Nina Ditsch

List of Publications by Year
in descending order

54 papers	5,536 citations	331670 21 h-index	175258 52 g-index
54 all docs	54 docs citations	54 times ranked	9809 citing authors

#	Article	IF	Citations
1	The role of E-Cadherin expression in primary site of breast cancer. Archives of Gynecology and Obstetrics, 2022, 305, 913-920.	1.7	5
2	Subcellular Distribution of Thyroid Hormone Receptor Beta in Ovarian Cancer. International Journal of Molecular Sciences, 2022, 23, 2698.	4.1	3
3	The Prognostic Impact of Retinoid X Receptor and Thyroid Hormone Receptor alpha in Unifocal vs. Multifocal/Multicentric Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 957.	4.1	12
4	First Evidence for a Role of Siglec-8 in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 2000.	4.1	3
5	Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs). Breast Cancer Research, 2021, 23, 45.	5.0	7
6	Cytoplasmic Localization of RXRα Determines Outcome in Breast Cancer. Cancers, 2021, 13, 3756.	3.7	7
7	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
8	Evaluation of the anti-Thomsen–Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer. Breast Cancer Research and Treatment, 2020, 179, 643-652.	2.5	0
9	L-Dopa-Decarboxylase (DDC) Is a Positive Prognosticator for Breast Cancer Patients and Epinephrine Regulates Breast Cancer Cell (MCF7 and T47D) Growth In Vitro According to Their Different Expression of Gi- Protein- Coupled Receptors. International Journal of Molecular Sciences, 2020, 21, 9565.	4.1	7
10	Expression of H3K4me3 and H3K9ac in breast cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2017-2027.	2.5	16
11	Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1923-1932.	2.5	8
12	EP3 Is an Independent Prognostic Marker Only for Unifocal Breast Cancer Cases. International Journal of Molecular Sciences, 2020, 21, 4418.	4.1	3
13	Cancer surveillance and distress among adult pathogenic <i>TP53</i> germline variant carriers in Germany: A multicenter feasibility and acceptance survey. Cancer, 2020, 126, 4032-4041.	4.1	20
14	Cytoplasmic PPARγ is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers. Journal of Translational Medicine, 2020, 18, 94.	4.4	19
15	Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor β1 Are Inversely Associated with Survival in Primary Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 330.	4.1	13
16	High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients. Cancers, 2020, 12, 953.	3.7	17
17	Placental Galectin-2 Expression in Gestational Diabetes: A Systematic, Histological Analysis. International Journal of Molecular Sciences, 2020, 21, 2404.	4.1	16
18	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Annals of Surgical Oncology, 2019, 26, 3892-3901.	1.5	29

#	Article	IF	Citations
19	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
20	<p>EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells</p>. OncoTargets and Therapy, 2019, Volume 12, 6053-6068.	2.0	12
21	Prognostic relevance of RIP140 and ERβ2 expression in unifocal versus multifocal breast cancers: a preliminary report. International Journal of Molecular Sciences, 2019, 20, 418.	4.1	8
22	Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	2.5	102
23	The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status. International Journal of Molecular Sciences, 2019, 20, 1016.	4.1	24
24	Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration . Breast Cancer: Targets and Therapy, 2019, Volume 11, 87-97.	1.8	13
25	Gene panel testing of 5589 <i><scp>BRCA</scp>1/2</i>â€negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Medicine, 2018, 7, 1349-1358.	2.8	126
26	Mutational spectrum in a worldwide study of 29,700 families with<i>BRCA1</i>or<i>BRCA2</i>mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
27	Prostaglandin E2 receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses. Endocrine Connections, 2018, 7, 749-761.	1.9	16
28	Evaluation of Reproductive Concerns and Biographical Impact of Breast Cancer in Young Patients. Breast Care, 2018, 13, 124-128.	1.4	4
29	EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. BMC Cancer, 2018, 18, 431.	2.6	15
30	Neoadjuvant radiotherapy followed by mastectomy and immediate breast reconstruction. Strahlentherapie Und Onkologie, 2017, 193, 324-331.	2.0	23
31	Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor Î³ are overexpressed in BRCA1 mutated breast cancer and predict prognosis. Journal of Experimental and Clinical Cancer Research, 2017, 36, 57.	8.6	24
32	Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1637-1647.	2.5	29
33	Association Between Loss-of-Function Mutations Within the <i>FANCM</i> Gene and Early-Onset Familial Breast Cancer. JAMA Oncology, 2017, 3, 1245.	7.1	74
34	Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis. Archives of Gynecology and Obstetrics, 2017, 296, 1135-1144.	1.7	22
35	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
36	Prevalence of<i>BRCA1/2</i>germline mutations in 21â€¦401 families with breast and ovarian cancer. Journal of Medical Genetics, 2016, 53, 465-471.	3.2	179

#	Article	IF	Citations
37	Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids. Journal of Translational Medicine, 2016, 14, 112.	4.4	38
38	p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1163-1170.	2.5	9
39	Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes. Anticancer Research, 2016, 36, 3185-90.	1.1	0
40	Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways. PLoS ONE, 2015, 10, e0127072.	2.5	32
41	Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEXâ„¢ is an independent prognostic marker for breast cancer patients. Journal of Experimental and Clinical Cancer Research, 2015, 34, 50.	8.6	14
42	The expression of thyroid hormone receptors (THR) is regulated by the progesterone receptor system in first trimester placental tissue and in BeWo cells in vitro. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 195, 31-39.	1.1	11
43	Expression of Thyroid Hormone Receptors in Villous Trophoblasts and Decidual Tissue at Protein and mRNA Levels Is Downregulated in Spontaneous and Recurrent Miscarriages. Journal of Histochemistry and Cytochemistry, 2015, 63, 511-523.	2.5	21
44	Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy â€" the SpheroNEO study. BMC Cancer, 2015, 15, 519.	2.6	26
45	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, The, 2014, 384, 164-172.	13.7	3,224
46	A retrospective investigation of womenâ€™s experience with breast reconstruction after mastectomy. Archives of Gynecology and Obstetrics, 2013, 287, 555-561.	1.7	13
47	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
48	Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer. Histology and Histopathology, 2013, 28, 227-37.	0.7	35
49	The Association between Vitamin D Receptor Expression and Prolonged Overall Survival in Breast Cancer. Journal of Histochemistry and Cytochemistry, 2012, 60, 121-129.	2.5	85
50	Germline RAD51C mutations confer susceptibility to ovarian cancer. Nature Genetics, 2012, 44, 476-476.	21.4	6
51	Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma. Oncology Letters, 2012, 4, 665-671.	1.8	19
52	How and for whom are decision aids effective? Long-term psychological outcome of a randomized controlled trial in women with newly diagnosed breast cancer.. Health Psychology, 2011, 30, 12-19.	1.6	29
53	Off-label use in germany - a current appraisal of gynaecologic university departments. European Journal of Medical Research, 2011, 16, 7.	2.2	6
54	Thyroid function in breast cancer patients. Anticancer Research, 2010, 30, 1713-7.	1.1	39